Skip to content

    Cervical Cancer Health Center

    Medical Reference Related to Cervical Cancer

    1. Endometrial Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - nci_ncicdr0000062938-nci-header

      This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Uterine Sarcoma Treatment

    2. Gestational Trophoblastic Disease Treatment (PDQ®): Treatment - Health Professional Information [NCI] - General Information About Gestational Trophoblastic Disease

      Gestational trophoblastic disease (GTD) is a broad term encompassing both benign and malignant growths arising from products of conception in the uterus. GTD may be classified as follows:[1]Hydatidiform mole (HM).Complete HM.Partial HM.Gestational trophoblastic neoplasia.Invasive mole.Choriocarcinoma.Placental-site trophoblastic tumor (very rare).Epithelioid trophoblastic tumor (even more rare).The reported incidence of GTD varies widely worldwide, from a low of 23 per 100,000 pregnancies (Paraguay) to a high of 1,299 per 100,000 pregnancies (Indonesia).[1] However, at least part of this variability is caused by differences in diagnostic criteria and reporting. The reported incidence in the United States is about 110 to 120 per 100,000 pregnancies. The reported incidence of choriocarcinoma, the most aggressive form of GTD, in the United States is about 2 to 7 per 100,000 pregnancies. The U.S. age-standardized (1960 World Population Standard) incidence rate of choriocarcinoma is

    3. Cervical Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Changes to This Summary (10 / 23 / 2014)

      No standard chemotherapy treatment that provides substantial palliation is available for patients with stage IVB cervical cancer. These patients are appropriate candidates for clinical trials testing single agents or combination chemotherapy employing agents listed below or new anticancer treatments in phase I and II clinical trials.[1]Standard treatment options:Radiation therapy may be used to palliate central disease or distant metastases. Chemotherapy. Tested drugs include the following:Cisplatin (15%–25% response rate).[1,2]Ifosfamide (31% response rate).[3]Paclitaxel (17% response rate).[4,5,6]Ifosfamide-cisplatin.[7,8]Irinotecan (21% response rate in patients previously treated with chemotherapy).[9]Paclitaxel/cisplatin (46% response rate).[10]Cisplatin/gemcitabine (41% response rate).[11]Cisplatin/topotecan (27% response rate).[12]Treatment options under clinical evaluation:New anticancer drugs in phase I and phase II clinical trials.Information about ongoing clinical trials

    4. Cervical Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - To Learn More About Cervical Cancer

      The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Editorial changes were made to this summary.

    5. Cervical Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Evidence of Benefit

      Measuring endometrial thickness (ET) with transvaginal ultrasound (TVU) and endometrial sampling with cytological examination have been proposed as possible screening modalities for endometrial cancer. The Papanicolaou (Pap) test, used successfully for screening for cervical cancer, is too insensitive to be used as a screening technique for the detection of endometrial cancer,[1] although occasionally the Pap test may fortuitously identify endometrial abnormalities, such as endometrial cancer. Routine screening of asymptomatic women for endometrial cancer has not been evaluated for its impact on endometrial cancer mortality.[2,3] Although high-risk groups can be identified, the benefit of screening in reducing endometrial cancer mortality in these high-risk groups has not been evaluated. Using the same cutoffs to define an abnormal ET in asymptomatic women [4] as used in symptomatic women [5] would result in large numbers of false-positive test results and larger numbers of

    6. Uterine Sarcoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage II Endometrial Cancer

      Standard treatment options:If cervical involvement is documented, options include radical hysterectomy, bilateral salpingo-oophorectomy, and pelvic and para-aortic lymph node dissection.If the cervix is clinically uninvolved but extension to the cervix is documented on postoperative pathology, radiation therapy should be considered.The completed GOG-LAP2 trial included 2,616 patients with clinical stage I to IIA disease and randomly assigned them two-to-one to comprehensive surgical staging via laparoscopy or laparotomy.[1] Time to recurrence was the primary endpoint, with noninferiority defined as a difference in recurrence rate of less than 5.3% between the two groups at 3 years. The recurrence rate at 3 years was 10.24% for patients in the laparotomy arm, compared with 11.39% for patients in the laparoscopy arm, with an estimated difference between groups of 1.14% (90% lower bound, -1.278; 95% upper bound, 3.996). Although this difference was lower than the prespecified limit, the

    7. Cervical Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - About This PDQ Summary

      About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current

    8. Cervical Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - About This PDQ Summary

      About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current

    9. Endometrial Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - nci_ncicdr0000062756-nci-header

      This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Cervical Cancer Screening

    10. Endometrial Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - nci_ncicdr0000062901-nci-header

      This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Gestational Trophoblastic Tumors Treatment

    Displaying 31 - 40 of 159 Articles << Prev Page 1 2 3 4 5 6 7 8 9 10 Next >>

    Today on WebMD

    cancer cell
    HPV is the top cause. Find out more.
    doctor and patient
    Get to know the symptoms.
     
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    Integrative Medicine Cancer Quiz
    QUIZ
    Lifestyle Tips for Depression Slideshow
    SLIDESHOW
     
    Screening Tests for Women
    Slideshow
    what is your cancer risk
    HEALTH CHECK